Innovative Drug Platform AQEMIA leverages a cutting-edge physics-based generative AI platform to discover novel medicines, particularly in complex disease areas such as oncology. This positions them as a leader in advanced drug discovery, presenting opportunities to collaborate or integrate with companies seeking innovative therapeutics.

Strategic Collaborations With active partnerships with top pharmaceutical firms and ongoing proprietary programs, AQEMIA demonstrates a robust pipeline and a track record of discovery success. Businesses aiming to expand their portfolio or co-develop new therapies should consider strategic alliances with AQEMIA.

Strong Growth Momentum Recent office expansions in London and significant funding milestones indicate rapidly increasing capacity and operational scale. This growth trajectory suggests an expanding market reach and potential for innovative research collaborations across Europe and beyond.

Funding and Investment Having secured nearly $100 million in funding, AQEMIA shows strong financial backing and investor confidence, providing a solid foundation for scaling up R&D efforts and commercializing breakthrough therapies—an appealing prospect for investors and partners focusing on biotech innovation.

Emerging Market Presence As part of the French Tech 120 and a member of prominent biotech associations, AQEMIA is positioned as an influential player in both the French and UK biotech ecosystems. This broad industry reach offers multiple channels for sales opportunities and collaborative ventures within vibrant science communities.